Navigation Links
GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
Date:8/7/2013

LONDON, Aug. 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on Wednesday, 14 August, 2013 at 2:00 p.m. ET. The conference will be held at the InterContinential Boston in Boston, MA.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section at www.gwpharm.com.

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
2. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
3. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
4. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. HealthEconomics.Com Launches a New Specialty Pharma Newsletter to Worldwide Community of Industry Insiders Within Specialty Pharmaceuticals
7. Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
8. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
9. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
10. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
11. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):